Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) has been given an average rating of “Moderate Buy” by the nine brokerages that are covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $6.56.
AKYA has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut Akoya Biosciences from an “overweight” rating to a “neutral” rating in a research note on Tuesday, August 6th. Piper Sandler reduced their target price on shares of Akoya Biosciences from $6.00 to $4.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Craig Hallum decreased their target price on shares of Akoya Biosciences from $7.50 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. BTIG Research cut Akoya Biosciences from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Finally, Morgan Stanley downgraded Akoya Biosciences from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $4.00 to $3.00 in a research report on Tuesday, August 6th.
Read Our Latest Research Report on AKYA
Institutional Inflows and Outflows
Akoya Biosciences Trading Down 1.0 %
NASDAQ AKYA opened at $2.88 on Friday. The company has a debt-to-equity ratio of 3.43, a quick ratio of 1.98 and a current ratio of 2.73. Akoya Biosciences has a one year low of $1.88 and a one year high of $6.31. The company has a 50-day simple moving average of $2.45 and a 200-day simple moving average of $3.09. The firm has a market capitalization of $142.23 million, a PE ratio of -1.96 and a beta of 1.35.
Akoya Biosciences (NASDAQ:AKYA – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported ($0.27) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.27). Akoya Biosciences had a negative return on equity of 126.38% and a negative net margin of 64.74%. The business had revenue of $23.16 million for the quarter, compared to analysts’ expectations of $23.61 million. During the same period in the prior year, the firm earned ($0.51) EPS. On average, equities analysts forecast that Akoya Biosciences will post -0.98 earnings per share for the current year.
Akoya Biosciences Company Profile
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Recommended Stories
- Five stocks we like better than Akoya Biosciences
- 3 Fintech Stocks With Good 2021 Prospects
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Earnings Per Share Calculator: How to Calculate EPS
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Golden Cross Stocks: Pattern, Examples and Charts
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.